Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine vs Donepezil in Mild to Moderate Alzheimer's Disease
NCT00035204Phase 4Completed
- Sponsor
- Johnson & Johnson
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 4, randomised, double-blind trial of galantamine in Alzheimer's disease (AD) (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Sleep Patterns, Attention and 1 more. Status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00035204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035204.